<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04862273</url>
  </required_header>
  <id_info>
    <org_study_id>DL-L-20006_V16</org_study_id>
    <nct_id>NCT04862273</nct_id>
  </id_info>
  <brief_title>Native T1 CMR Imaging for Diagnosis of Cardiac Amyloidosis</brief_title>
  <acronym>CMR for CA</acronym>
  <official_title>Native T1 Cardiac Magnetic Resonance Imaging for Diagnosis of Cardiac Amyloidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Leipzig</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Leipzig</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to test the diagnostic accuracy of native T1 mapping for the diagnosis of&#xD;
      cardiac amyloidosis prospectively. The hypothesis is that native T1 mapping with a cut-off&#xD;
      value of 1341ms (3 tesla CMR) in older patients with symptomatic heart failure, increased LV&#xD;
      wall thickness and elevated cardiac biomarkers is non-inferior to the reference method to&#xD;
      diagnose cardiac amyloidosis (CA).&#xD;
&#xD;
      As secondary measure, a web-based ATTR probability estimator for the diagnosis of CA will be&#xD;
      evaluated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiac amyloidosis (CA) is an important differential diagnosis in older patients with&#xD;
      symptomatic heart failure with preserved or mid-range ejection fraction and increased left&#xD;
      ventricular wall thickness. The prevalence of CA among patients with heart failure and left&#xD;
      ventricular (LV) hypertrophy is approximately 13%. However, diagnosis of CA is challenging&#xD;
      because specific clinical signs are often lacking.&#xD;
&#xD;
      Amyloid fibrils deposit in the extracellular space of the myocardium increases myocardial T1&#xD;
      values on cardiac magnetic resonance (CMR). Therefore, native T1 imaging provides a promising&#xD;
      non-invasive method to identify CA.&#xD;
&#xD;
      A preliminary retrospective analysis of 128 patients with increased LV wall thickness&#xD;
      identified an area under the curve of 0.9954 (p&lt;0.0001) for native T1 to detect CA. The&#xD;
      optimal cut-off value was 1341ms, with a sensitivity of 100% and a specificity of 97%.&#xD;
&#xD;
      The investigators aim to test the diagnostic accuracy of native T1 mapping with the threshold&#xD;
      of 1341ms for the diagnosis of CA compared to the reference method prospectively. Moreover,&#xD;
      the web-based ATTR probability estimator for the diagnosis of CA will be evaluated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic accuracy of native T1 LV mapping for diagnosis of CA</measure>
    <time_frame>up to 7 days</time_frame>
    <description>Comparison native T1 CMR with the reference method for diagnosis of CA</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diagnostic accuracy of ATTR probability estimator to predict CA</measure>
    <time_frame>up to 7 days</time_frame>
    <description>Comparison of a probability score to predict ATTR with the final diagnosis of ATTR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of native T1 values with cardiovascular outcome</measure>
    <time_frame>1 years</time_frame>
    <description>All-cause death, cardiovascular death and heart failure hospitalizations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of ATTR probability estimator values with cardiovascular outcome</measure>
    <time_frame>1 year</time_frame>
    <description>All-cause death, cardiovascular death and heart failure hospitalizations</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Heart Failure NYHA Class II</condition>
  <condition>Heart Failure NYHA Class III</condition>
  <condition>Heart Failure NYHA Class IV</condition>
  <condition>Heart Failure With Preserved Ejection Fraction</condition>
  <condition>Heart Failure With Mid Range Ejection Fraction</condition>
  <condition>Hypertrophy, Left Ventricular</condition>
  <condition>Cardiac Amyloidosis</condition>
  <arm_group>
    <arm_group_label>Native T1 CMR</arm_group_label>
    <description>Diagnostic accuracy of native T1 CMR and ATTR probability estimator are tested against the reference methods (99mTc-DPD scintigraphy, laboratory screening for multiple myeloma / AL amyloidosis; or cardiac biopsy, if noninvasive evaluation is inconclusive)</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Native T1 CMR</intervention_name>
    <description>Observed method</description>
    <arm_group_label>Native T1 CMR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Web-based ATTR probability estimator (Pfizer, New York)</intervention_name>
    <description>Observed method</description>
    <arm_group_label>Native T1 CMR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>99mTc-DPD scintigraphy</intervention_name>
    <description>Reference method</description>
    <arm_group_label>Native T1 CMR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Laboratory screening for multiple myeloma / AL amyloidosis</intervention_name>
    <description>Reference method</description>
    <arm_group_label>Native T1 CMR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cardiac biopsy</intervention_name>
    <description>If non-invasive tests for CA (99mTc-DPD scintigraphy, biochemistry) are inconclusive</description>
    <arm_group_label>Native T1 CMR</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with symptomatic heart failure (NYHA functional class II to IV, LVEF ≥40%),&#xD;
        increased left ventricular wall thickness and elevated cardiac biomarkers&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 60 years&#xD;
&#xD;
          -  Symptomatic heart failure (NYHA II-IV) with LVEF ≥40%&#xD;
&#xD;
          -  Increased LV wall thickness (≥12mm end-diastolic)&#xD;
&#xD;
          -  NT-proBNP ≥1000pg/mL&#xD;
&#xD;
          -  Elevated hs-troponin T ≥14ng/L&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindications for CMR&#xD;
&#xD;
          -  Acute myocarditis&#xD;
&#xD;
          -  Acute myocardial infarction &lt;1 month&#xD;
&#xD;
          -  Severe aortic stenosis and RAISE score &lt; 2 points&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Daniel Lavall, MD</last_name>
    <phone>+493419712650</phone>
    <email>Daniel.Lavall@medizin.uni-leipzig.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Romy Langhammer, MD</last_name>
    <phone>+493419712650</phone>
    <email>Romy.Langhammer@medizin.uni-leipzig.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Leipzig</name>
      <address>
        <city>Leipzig</city>
        <state>Saxony</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Lavall, MD</last_name>
      <phone>+493419712650</phone>
      <email>Daniel.Lavall@medizin.uni-leipzig.de</email>
    </contact>
    <contact_backup>
      <last_name>Romy Langhammer, MD</last_name>
      <phone>+493419712650</phone>
      <email>Romy.Langhammer@medizin.uni-leipzig.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 20, 2021</study_first_submitted>
  <study_first_submitted_qc>April 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2021</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Leipzig</investigator_affiliation>
    <investigator_full_name>Daniel Lavall</investigator_full_name>
    <investigator_title>Cardiologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Hypertrophy, Left Ventricular</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

